{"entity":{"id":"shy-therapeutics","kind":"company","name":"SHY Therapeutics","aka":["SHY Therapeutics, LLC"],"tldr":"SHY Therapeutics develops small-molecule medicines taken by mouth. Its lead, SHY-ONC6, blocks part of the proteasome, the cell's protein-recycling machine, and is in an early trial in advanced solid tumours.","summary":"SHY Therapeutics, LLC, of Valhalla, New York, with laboratory work on the New York Medical College campus, develops small molecules from a proprietary platform of pharmacophores that non-covalently modulate ATPases and GTPases. Its lead, SHY-ONC6, is described as an oral small-molecule inhibitor of proteasome ATPases; the company announced in August 2026 that the first patient had been dosed in its phase 1 trial, Luca-1 (NCT07705334), which gives SHY-ONC6 once daily in 21-day cycles to adults with advanced or metastatic solid tumours including triple-negative and HR-positive breast, colon and gastric cancers. Its pipeline also includes a multi-target Ras superfamily GTPase cancer programme in lead optimisation and non-oncology programmes in anti-infectives and neuromuscular disease. Its first registered cancer trial, NCT07705334, was posted on ClinicalTrials.gov in July 2026.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.shytherapeutics.com/"},{"label":"First patient dosed with SHY-ONC6, August 2026","url":"https://www.shytherapeutics.com/news/shy-therapeutics-first-patient-dosed-in-phase-1-clinical-trial"},{"label":"ClinicalTrials.gov: phase 1 trial of SHY-ONC6 (NCT07705334)","url":"https://clinicaltrials.gov/study/NCT07705334"}],"tags":[],"related":[],"cancers":["breast-cancer","colorectal","gastric"],"sections":["targeted-therapy"],"technologies":[],"targets":["proteasome"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["OnCo has no technology record for proteasome inhibitors; the link to cytotoxic chemotherapy is the nearest fit and should be revisited.","Founding year and financing not stated on the company website; the launch release linked from the website returned HTTP 404 on 29 October 2026."],"hq":"Valhalla, NY","country":"US","companyType":"biotech","website":"https://www.shytherapeutics.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/shy-therapeutics/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"proteasome","kind":"target","name":"Proteasome (PSMB5)","route":"/targets/proteasome/"}]}}